Quest Diagnostics turned a bigger quarter into a much bigger cash pile

Quest Diagnostics, a US provider of diagnostic laboratory testing, ended Q3 2026 with cash of USD 797m, against USD 432m a year earlier. Revenue for the quarter was USD 3.1bn, up 10.0% on Q3 2025. Operating profit rose 24.1% to USD 479m, and net profit rose 27.3% to USD 312m. All figures are consolidated, in US dollars, under US GAAP. Cash grew far faster than sales, which is the order a controller prefers to see.

Lab testing is a high-volume business with heavy fixed costs: labs, equipment, couriers and staff. When more tests pass through the same network, each extra dollar of revenue tends to leave more profit behind. The operating margin moved to 15.5% from 13.7%, which fits that pattern. The equity ratio eased to 44.3% from 44.8%, so assets grew slightly faster than equity. The accounts do not show what drove the cash increase. I would watch whether it holds in the next quarter.